Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 21, 2026 is 275.52 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 284.19 % — a change of -3.05% (lower).

Cash Conversion

275.52 %

YoY

-3.05%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp is 2025 275.52 % . Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp was 2024 284.19 % . It decreases by -3.05% lower compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
219.54 CNY
Jan 1, 2019
485.95 CNY
Jan 1, 2020
-192.61 CNY
Jan 1, 2021
206.64 CNY
Jan 1, 2022
231.79 CNY
Jan 1, 2023
280.89 CNY
Jan 1, 2024
284.19 CNY
Jan 1, 2025
275.52 CNY
The Vcanbio Cell & Gene Engineering Corp Cash Conversion history
YEARCash ConversionYoY
275.52 %-3.05%
284.19 %+1.17%
280.89 %+21.18%
231.79 %+12.17%
206.64 %-207.28%
-192.61 %-139.64%
485.95 %+121.35%
219.54 %-67.61%
677.85 %+78.63%
379.47 %+9,571.50%
3.92 %-99.37%
624.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp is 275.52 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Vcanbio Cell & Gene Engineering Corp changed from 284.19 % to 275.52 %, representing a -3.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp